Candoxatril

DB00616ExperimentalSmall molecule

Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

Mechanism: Neutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.
Curator reviewed
Formula / weight: C₂₉H₄₁NO₇ · 515.6383 g/mol (avg)
Code names: UK-79,300

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyZTWZVMIYIIVABD-OEMFJLHTSA-NSMILESCOCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1

Targets

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

633Drug interactionsStructured to mechanism, not free text

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Candoxatril, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.